NCT00003936

Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Barbara Ann Karmanos Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have recurrent or refractory Hodgkin's disease.

Detailed description

OBJECTIVES: I. Determine the response rate in patients with recurrent or refractory Hodgkin's disease treated with bryostatin 1. II. Determine qualitative and quantitative toxicities of bryostatin 1 in these patients. III. Determine duration of response and survival in these patients. OUTLINE: Patients receive bryostatin 1 by continuous IV infusion over 72 hours. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity for at least 4 courses. Patients who achieve complete response (CR) are treated with 4 additional courses beyond CR. PROJECTED ACCRUAL: A total of 14-27 patients will be accrued for this study within 2 years.

Conditions

• Lymphoma

Interventions

Type	Name	Description
DRUG	bryostatin 1

Timeline

• Start date: 1999-06-01
• Primary completion: 2004-06-01
• Completion: 2004-06-01
• First posted: 2004-07-26
• Last updated: 2014-04-11

Locations

1 site across 1 country: United States